Meetings

The International Society for Stem Cell Research (ISSCR) today announced that the ISSCR 2027 Annual Meeting is coming back to San Francisco, USA, 15-18 June 2027. Recognized as the premier international forum for stem cell science, the gathering will recognize 25 years of discovery, collaboration, and progress in stem cell science and gather the people, ideas, and work that will shape the next quarter century.

Tirzepatide GLP-1 medication is known to improve sleep apnea for people with both obstructive sleep apnea (OSA) and obesity, but not all patients benefit equally

A large new study presented at the 2026 ATS International Conference shows that patients treated for COPD or pneumonia experience worse outcomes across several important measures when they are treated at hospitals that have been acquired by private equity firms.

The drug tezepelumab was shown to significantly reduce exacerbations in people with severe asthma in clinical trials. Now, a new study presented at the 2026 ATS International Conference shows that it is also safe and effective in real-world patients. “Tezepelumab in Real-World U.S. Patients with Severe Asthma Across Phenotypes and Underrepresented Populations: The Phase 4 PASSAGE Study” will be published in the American Journal of Respiratory and Critical Care Medicine online on May 18.

A once-nightly oral pill helped control obstructive sleep apnea in a large, phase 3 clinical trial presented at the 2026 ATS International Conference. The drug, called AD109, is the first therapy to treat OSA by addressing its underlying mechanisms and targeting the neuromuscular causes of airway collapse. “Aroxybutynin and Atomoxetine (AD109) for Obstructive Sleep Apnea: A Randomized Phase 3 Trial” will be published in the American Journal of Respiratory and Critical Care Medicine.

New research presented at the 2026 ATS International Conference shows that pulmonary rehabilitation (PR) significantly improves functioning and quality of life in children with chronic respiratory conditions, regardless of whether lung function itself improves.

The impacts of tuberculosis (TB) are usually discussed in terms of public health and human suffering. Now, new research presented at the 2026 ATS International Conference shows that TB is also driving a massive global economic crisis.

The New York City Housing Authority developed Mold Busters, a mold-removal program, in response to a 2013 class-action lawsuit filed by residents suffering from asthma due to mold in their apartments. New research presented at the ATS 2026 International Conference shows that the program results in nearly 2,800 fewer asthma-related emergency department visits annually.

More than a student event or hospital outreach effort, Paediatric Brain and Solid Tumour Awareness (PBSTA) Day has become a growing community of support for children living with cancer and the families who care for them.

Registration opens today for the 68^th American Society for Radiation Oncology (ASTRO) Annual Meeting, the leading global conference in radiation oncology. The conference will be held at the Thomas M. Menino Convention & Exhibition Center in Boston, September 26-30, 2026. Complimentary media registration is available for qualified journalists.

Dear Experts and Colleagues,

    We are pleased to invite you to present and participate in our first annual Experimental Therapeutics at Ruijin meeting, to be held on June 1st to 4th,  2026, at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Annual meeting will bring together leading investigators to share experiences in translating scientific discoveries into clinical success. We hope the event will provide every participant—faculty, students, and guests alike—with valuable insights and a stimulating exchange of ideas. The organizers are:

    H. Michael Shepard, PhD – Experimental Therapeutics Group, Ruijin Hospital, Shanghai

    Baiyong Shen, MD – Professor and Chief Physician, Ruijin Hospital, Shanghai

    Mone Zaidi, PhD – Icahn School of Medicine at Mount Sinai, New York

    We anticipate a high level of interest in this topic and will provide ample opportunity for meaningful interaction and discussion among participants. Some presentations will highlight programs with regulatory approval, while most will focus on those with preclinical or early clinical proof of concept.

    We sincerely hope you can join us for this exciting event in Shanghai.

    Time: June 1st to 4th, 2026

    Location: 1F Lecture Hall, Building 35, Translational Medicine Building, No. 197 Ruijin 2nd Road, Ruijin Hospital, Shanghai, China

    Contact: ying.zhang@jueqianmed.com